My research at the Sanger Institute focuses on understanding the human intestinal microbiota in health and in disease. In particular, my PhD project focuses on the development of a bacteriotherapy for the treatment of severe Clostridium difficile disease using a range of bioinformatics and molecular based techniques. Knowing the bacterial species that can confer colonization resistance against C. difficile is important, as a major cause of this disease, is antibiotic disruption of the intestinal microbiota.